BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer
No Thumbnail Available
Identifiers
Date
2021-09-21
Authors
Schmid, P.
Salvador Bofill, J.
Bermejo, B.
Phillips, M.
Wheatley, D.
Neus, F.
Schem, C.
Stradella, A.
Mele, M.
Cortes Salgado, A.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
